Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241519 | 1.00 | SCN4A (0.43) | SCN4ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL6260458 | 0.99 | SCN4A (0.42) | SCN4ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23299367 | 0.86 | SCN5A (0.38) | SCN4ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23299355 | 0.86 | SCN5A (0.38) | SCN4ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23299333 | 0.83 | SLC6A3 (0.39) | — | |
| SCHEMBL28049435 | 0.81 | SCN5A (0.42) | SCN5ASCN9ASCN10A | |
| SCHEMBL17551731 | 0.78 | SCN4A (0.35) | SCN4ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3160590 | 0.77 | PRCP (0.48) | — | |
| SCHEMBL17598343 | 0.76 | SCN4A (0.34) | SCN4ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| Propofol SCHEMBL2678239 | 0.76 | SLC6A2 (0.49) | SCN4ACYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2007089745-A2 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R & D HOLDINGS, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20060241017-A1 | Novel compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1660017-A2 | AMINO ACID PRODRUGS | Signature R&D Holdings, LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005046575-A2 | AMINO ACID PRODRUGS | SIGNATURE R & D HOLDINGS, LCC (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | IL4I1, SLC7A1, GOT1 | SCN4A 4241/4885CYP1A2 2425/4885CYP3A4 1810/4885 |
| US-20060241017-A1 | Novel compounds with high therapeutic index | IL4I1, SLC7A1, GOT1 | SCN4A 4241/4885CYP1A2 2425/4885CYP3A4 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.